Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
IPCA Laboratories Limited
IPCALABIpca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India. Address: 125, Kandivli Industrial Estate, Mumbai, India, 400067
Analytics
WallStreetin tavoitehinta
123 725.21 INRP/E-suhde
67.5704Osinkotuotto
0.26 %Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut IPCALAB
Osinkoanalytiikka IPCALAB
Osinkojen kasvu 5 vuoden aikana
300 %Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
13 %Osinkohistoria IPCALAB
Osakkeen arvostus IPCALAB
Talousasiat IPCALAB
Tuloksia | 2019 | Dynamiikka |